Merck kicks off lung-cancer campaign

Merck kicks off lung-cancer campaign

On the heels of Keytruda's approval in first-line lung cancer, the drugmaker kicked off an unbranded campaign raising awareness about biomarkers.

Five things for pharma marketers to know: Friday, December 9, 2016

Five things for pharma marketers to know: Friday, December 9, 2016

BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA

How pharma can stay compliant when using programmatic

How pharma can stay compliant when using programmatic

The risk of fraud is also very real, especially in an industry that already faces privacy and compliance challenges, one expert says.

Five things for pharma marketers to know: Thursday, December 8, 2016

Five things for pharma marketers to know: Thursday, December 8, 2016

A California lawmaker reintroduces drug-pricing bill; France, Poland, Spain, and Sweden lobby to host EMA; drug stocks fall after Trump's comments

An EHR strategy can't be measured in clicks, says Lilly exec

An EHR strategy can't be measured in clicks, says Lilly exec

Pharma can reach physicians within the EHR, but they must send the right message at the right time, she said at an MM&M event.

Spectrum names Jonathan Wilson CEO

Spectrum names Jonathan Wilson CEO

Wilson will succeed founder and CEO John Seng.

W2O Group acquires Sentient Interactive

W2O Group acquires Sentient Interactive

This is W2O Group's third acquisition since a private-equity firm took an investment in May.

Senate passes Cures Act, which opens door to use of real-world evidence

Senate passes Cures Act, which opens door to use of real-world evidence

The bill now heads to President Obama's desk. He is expected to sign the sweeping piece of legislation.

Five things for pharma marketers to know: Wednesday, December 7, 2016

Five things for pharma marketers to know: Wednesday, December 7, 2016

Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine

GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials

GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials

The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.

Five things for pharma marketers to know: Tuesday, December 6, 2016

Five things for pharma marketers to know: Tuesday, December 6, 2016

Prices of Viagra and Cialis triple since 2010; AstraZeneca's Tagrisso slows lung-cancer progression compared to chemo; Novo Nordisk to limit price increases

Rock Health's Bill Evans on finding a career with meaning

Rock Health's Bill Evans on finding a career with meaning

The Roche veteran says that people who work in digital health need to touch others in a meaningful way.

Matt Brown leaves Guidemark Health after merger falls through

Matt Brown leaves Guidemark Health after merger falls through

The agency is owned by High Road Capital Partners. Sophy Regelous, the company's chief operating officer, will now lead the agency.

Five things for pharma marketers to know: Monday, December 5, 2016

Five things for pharma marketers to know: Monday, December 5, 2016

The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy

Prescription drug spending rises 9% in 2015, to $324 billion

Prescription drug spending rises 9% in 2015, to $324 billion

However, the rate of drug spending slowed compared to last year, according to an analysis by the CMS.

As users move to mobile, Google says they made 200 million queries for info about cancer drugs

As users move to mobile, Google says they made 200 million queries for info about cancer drugs

The search-engine giant says that one in 20 online searches are related to healthcare, and more users are using mobile to consume media.

Five things for pharma marketers to know: Friday, December 2, 2016

Five things for pharma marketers to know: Friday, December 2, 2016

Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.

Five things for pharma marketers to know: Thursday, December 1, 2016

Five things for pharma marketers to know: Thursday, December 1, 2016

Valeant doesn't plan to offload Salix; heart docs back Califf as commish; Saunders says pricing issues aren't affected by election

House passes 21st Century Cures Act that would allow some off-label sharing

House passes 21st Century Cures Act that would allow some off-label sharing

The bill includes two provisions that would address drugmakers' calls for clarity on sharing off-label information with payers and regulators.

MM&M's top 5 stories in November 2016

MM&M's top 5 stories in November 2016

How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Lilly's branded app for Trulicity looks to address adherence

Lilly's branded app for Trulicity looks to address adherence

Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.

Lawmakers cut CME exemption from 21st Century Cures Act

Lawmakers cut CME exemption from 21st Century Cures Act

The bill includes provisions to investigate the usefulness of off-label information but will no longer exempt drugmakers from reporting CME payments.

How Duchesnay USA got over the Kardashian marketing bump

How Duchesnay USA got over the Kardashian marketing bump

The drugmaker still views Instagram as a viable marketing platform, however.

Five things for pharma marketers to know: Tuesday, November 29, 2016

Five things for pharma marketers to know: Tuesday, November 29, 2016

Trump selects Price as head of HHS; Warren criticizes 21st Century Cures; GSK CEO says companies will have to get used to making less money

Gilead's Meyers on making deals and finding unmet patient needs

Gilead's Meyers on making deals and finding unmet patient needs

The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.

Five things for pharma marketers to know: Monday, November 28, 2016

Five things for pharma marketers to know: Monday, November 28, 2016

J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe

U.S. marketers spend slightly less on digital engagement with docs than China

U.S. marketers spend slightly less on digital engagement with docs than China

A new survey found that U.S. pharma marketers prefer using social media and mobile apps to reach healthcare providers.

Five things for pharma marketers to know: Wednesday, November 23, 2016

Five things for pharma marketers to know: Wednesday, November 23, 2016

Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.

Infographic: The physician view on EHRs

Infographic: The physician view on EHRs

Most physicians said EHRs have negatively impacted their communication with a patients.

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Walgreens.com to publish patient reviews of drug effectiveness

Walgreens.com to publish patient reviews of drug effectiveness

The drugstore chain added drug effectiveness reviews and other information from PatientsLikeMe to its website.

Five things for pharma marketers to know: Monday, November 21, 2016

Five things for pharma marketers to know: Monday, November 21, 2016

Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel

Five things for pharma marketers to know: Friday, November 18, 2016

Five things for pharma marketers to know: Friday, November 18, 2016

Chicago requires pharma rep to have licenses, Acorda CEO backs Califf to remain FDA commish, high-prescribing medicare docs are on the rise

ContextMedia to acquire AccentHealth to grow its position in the point-of-care market

ContextMedia to acquire AccentHealth to grow its position in the point-of-care market

As part of the acquisition, 160 AccentHealth employees will join ContextMedia, which has a staff of about 500 people.

Five things for pharma marketers to know: Thursday, November 17, 2016

Five things for pharma marketers to know: Thursday, November 17, 2016

Former Valeant and Philidor execs arrested; at least 1 million enroll in 2017 exchange plans; mobile game helps scientists study dementia

Physicians still rely on medical journals but turn to the web when they have only 10 minutes

Physicians still rely on medical journals but turn to the web when they have only 10 minutes

Drugmakers can do a better job of organizing dosing information, safety information, and clinical data on their brand websites, a new survey found.

Physicians call for value-based drug pricing

Physicians call for value-based drug pricing

The largest group of U.S. physicians said drug pricing needs to align with the broader healthcare industry's drive for value.

Five things for pharma marketers to know: Wednesday, November 16, 2016

Five things for pharma marketers to know: Wednesday, November 16, 2016

The AMA votes in favor of value-based drug pricing; Amgen says insurers are balking at PCSK9 inhibitor prices; docs aren't focused on prices when prescribing

Amgen's Repatha lowers plaque in arteries

Amgen's Repatha lowers plaque in arteries

New clinical data showed that Repatha, a PCSK9 inhibitor, reduced plaque in arteries when combined with a statin.

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.

Five things for pharma marketers to know: Tuesday, November 15, 2016

Five things for pharma marketers to know: Tuesday, November 15, 2016

The CMS spent more on Harvoni than any other drug; Novartis considers selling Alcon; the EMA recommends approval of Lantus biosimilar

PulsePoint launches health vertical for programmatic advertising

PulsePoint launches health vertical for programmatic advertising

The programmatic advertising technology company also hired Chris Neuner as SVP and GM of digital health.

Pfizer expands humanitarian access to Prevnar 13 vaccine

Pfizer expands humanitarian access to Prevnar 13 vaccine

Pfizer expanded its humanitarian efforts by providing the Prevnar 13 vaccine at a low price and donating proceeds to aid groups.

Five things for pharma marketers to know: Monday, November 14, 2016

Five things for pharma marketers to know: Monday, November 14, 2016

J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader

Pharma pushes to share off-label info with payers at FDA hearing

Pharma pushes to share off-label info with payers at FDA hearing

Insurers and pharmacy benefit managers already have a sophisticated understanding of clinical data, the industry argued.

Five things for pharma marketers to know: Friday, November 11, 2016

Five things for pharma marketers to know: Friday, November 11, 2016

Trump says he will reform the FDA; pharmaceutical M&A expected to pick up; superbug causing infections in cystic-fibrosis patients

5 questions raised at the FDA's off-label hearing

5 questions raised at the FDA's off-label hearing

The FDA asked questions about the risks and benefits of allowing off-label communications.

Five things for pharma marketers to know: Thursday, November 10, 2016

Five things for pharma marketers to know: Thursday, November 10, 2016

Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions

The drug industry wins pricing battle in California, likely to fare better with Trump

The drug industry wins pricing battle in California, likely to fare better with Trump

But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.

Five things for pharma marketers to know: Wednesday, November 9, 2016

Five things for pharma marketers to know: Wednesday, November 9, 2016

Trump, a critic and supporter of pharma, wins election; pharma's futures rise in election's wake; drug-pricing measure in California likely to be defeated

Huntsworth Health's ApotheCom partners with Continuum Clinical

Huntsworth Health's ApotheCom partners with Continuum Clinical

The partnership will span ApotheCom's offices around the world, including those in the U.S., U.K., and Asia.

Five things for pharma marketers to know: Tuesday, November 8, 2016

Five things for pharma marketers to know: Tuesday, November 8, 2016

FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast

How Ascension's Nick Ragone is rebranding one of the biggest U.S. health systems

How Ascension's Nick Ragone is rebranding one of the biggest U.S. health systems

The health system is one of the largest in the country. Most of Ascension's hospitals, Ragone says, used to operate almost independently from each other and the company's headquarters.

Five things for pharma marketers to know: Monday, November 7, 2016

Five things for pharma marketers to know: Monday, November 7, 2016

Bayer submits Stivarga to FDA for liver-cancer indication; emails show FDA's divisiveness over Duchenne drug approval; insurers want new president to address ACA financial risks

Off-label promotion: By the numbers

Off-label promotion: By the numbers

Here are 5 statistics about off-label promotion ahead of the FDA's public hearing this week.

Will drugmakers get what they're looking for at this week's FDA off-label hearing?

Will drugmakers get what they're looking for at this week's FDA off-label hearing?

Spurred by recent lawsuits, the FDA is scheduled to hold a two-day hearing this week on whether to allow drugmakers more latitude in promoting therapies off-label.

FDA charges KOL with misbranding seizure drug in promo video

FDA charges KOL with misbranding seizure drug in promo video

Supernus Pharmaceuticals received an untitled letter over a promotional video for Oxtellar XR.

Five things for pharma marketers to know: Friday, November 4, 2016

Five things for pharma marketers to know: Friday, November 4, 2016

Pharma may face price-collusion charges; FDA approval team can't fill vacancies; OPDP issues letter over promo video

Five things for pharma marketers to know: Thursday, November 3, 2016

Five things for pharma marketers to know: Thursday, November 3, 2016

Sprout investors sue Valeant; FDA raises safety concerns for Cempra's experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients

10 things for pharma marketers to know about Facebook and Instagram

10 things for pharma marketers to know about Facebook and Instagram

With about 70 million users in six million health-related groups, drugmakers have tremendous opportunity to reach key audiences on Facebook. Here's how.

With more marketing spend behind it, Eliquis gains on market leader Xarelto

With more marketing spend behind it, Eliquis gains on market leader Xarelto

BMS and Pfizer outspent Johnson & Johnson two-to-one in advertising for their oral anticoagulant last year.

Five things for pharma marketers to know: Wednesday, November 2, 2016

Five things for pharma marketers to know: Wednesday, November 2, 2016

Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences

Timeline of a crisis: How Mylan responded to the EpiPen controversy

Timeline of a crisis: How Mylan responded to the EpiPen controversy

Mylan was slammed by people unable to afford its lifesaving EpiPen injection device following a price hike — its response was seen as too little, too late.

Five things for pharma marketers to know: Tuesday, November 1, 2016

Five things for pharma marketers to know: Tuesday, November 1, 2016

Facebook opens up to pharma; Pfizer nixes PCSK9 inhibitor in development; Cardinal Health cuts forecast on dwindling price increases

Marvel creates superheroes suffering from bowel disease for Takeda campaign

Marvel creates superheroes suffering from bowel disease for Takeda campaign

Takeda launched four new superheroes whose lives have been touched by inflammatory bowel disease (IBD), with the help of PR agency Ketchum.

Five things for pharma marketers to know: Monday, October 31, 2016

Five things for pharma marketers to know: Monday, October 31, 2016

Shares decline on news drugmakers will limit price hikes; AstraZeneca said it will leave UK if country doesn't pay for new drugs; Astellas acquires Ganymed

Astellas boosts pharma's rep with corporate branding push

Astellas boosts pharma's rep with corporate branding push

The new TV spot was developed with CNN and Edelman.

Five things for pharma marketers to know: Friday, October 28, 2016

Five things for pharma marketers to know: Friday, October 28, 2016

Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle

Warning letters most often stem from missing risk information

Warning letters most often stem from missing risk information

The number of warning and untitled letters has dropped in recent years. Only four letters have been sent so far this year, compared to 28 in 2012.

Five things for pharma marketers to know: Thursday, October 27, 2016

Five things for pharma marketers to know: Thursday, October 27, 2016

BIO released a video explaining drug costs; the FDA commits to shorter generic approval process; Kaléo to launch EpiPen competitor

Drugmakers spar with FDA over proposed DTC animation study

Drugmakers spar with FDA over proposed DTC animation study

The FDA responded to criticism from industry about its proposed research of DTC animation.

Ketchum promotes McCarthy, hires new head of healthcare

Ketchum promotes McCarthy, hires new head of healthcare

Tom Jones joined Ketchum after serving as head of healthcare at Makovsky.

How Excedrin brought VR to drug marketing with The Migraine Experience

How Excedrin brought VR to drug marketing with The Migraine Experience

While VR is only just getting started, some marketers are already embracing its potential to offer an immersive experience for far-off future campaigns.

Five things for pharma marketers to know: Wednesday, October 26, 2016

Five things for pharma marketers to know: Wednesday, October 26, 2016

Novartis CEO said pricing environment to worsen; Purdue Pharma offered PBM rebates to get around oxycodone prior authorization; Express Scripts subpoenaed

Merck Consumer Health CMO on who makes healthcare decisions

Merck Consumer Health CMO on who makes healthcare decisions

Merck Consumer Health CMO Atilla Cansun also talks about about why the company is focused on preparing society for an average lifespan of 100 years.

Five things for pharma marketers to know: Tuesday, October 25, 2016

Five things for pharma marketers to know: Tuesday, October 25, 2016

Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health

Sunovion hires former BI exec as VP of marketing

Sunovion hires former BI exec as VP of marketing

Denise Strauss, formerly VP of cardiovascular marketing at Boehringer Ingelheim, will oversee the drugmaker's marketing activities.

Merck's Keytruda wins approval in first-line lung cancer

Merck's Keytruda wins approval in first-line lung cancer

Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.

J&J exec calls California pricing measure 'misguided'

J&J exec calls California pricing measure 'misguided'

Voters are set to vote on Proposition 61, which would allow state agencies to pay the same prices for drugs that the VA department pays.

Five things for pharma marketers to know: Monday, October 24, 2016

Five things for pharma marketers to know: Monday, October 24, 2016

GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus

Five things for pharma marketers to know: Friday, October 21, 2016

Five things for pharma marketers to know: Friday, October 21, 2016

Lawmakers ask for information about price of leukemia drug; Abbott writes down losses from Mylan stake; CVS Health focused on role as health brand

Why Excedrin embraced the headache of a contentious election season

Why Excedrin embraced the headache of a contentious election season

Excedrin's #DebateHeadache was inspired by complaints the brand noticed during the first presidential debate in September.

Five things for pharma marketers to know: Thursday, October 20, 2016

Five things for pharma marketers to know: Thursday, October 20, 2016

Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug

StartUp Health reports more global deals, uptick in pharma investment in digital health

StartUp Health reports more global deals, uptick in pharma investment in digital health

More acquisitions, less IPOs, and more non-traditional stakeholders are among key findings from StartUp Health and Rock Health about the state of digital health funding.

Five things for pharma marketers to know: Wednesday, October 19, 2016

Five things for pharma marketers to know: Wednesday, October 19, 2016

Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market

The 50-plus consumer is driven by curiosity and wonder, finds Ketchum study

The 50-plus consumer is driven by curiosity and wonder, finds Ketchum study

In the United States, people over 50 are often stereotyped as complacent, set in their ways and extremely loyal to their preferred brands, but a new study released Tuesday by Ketchum found that the opposite is true.

Five things for pharma marketers to know: Tuesday, October 18, 2016

Five things for pharma marketers to know: Tuesday, October 18, 2016

Pfizer to start selling Remicade biosimilar in November; The Medicines Co.'s PCSK9 inhibitor heads to Phase-III trials; J&J's Q3 growth bolstered by autoimmune drugs

Guidemark Health merges with three companies to form new agency

Guidemark Health merges with three companies to form new agency

Guidemark Health, Bluespire, Bluespire Senior Living, and Ariad Communications will merge under a new entity.

Five things for pharma marketers to know: Monday, October 17, 2016

Five things for pharma marketers to know: Monday, October 17, 2016

Doctors Without Borders refuses free Pfizer vaccines; Valeant to raise prices of certain drugs; two urologists advocate for overactive bladder drugs

Cleveland Clinic's Cosgrove: Obamacare now 'part of the fabric' of the U.S.

Cleveland Clinic's Cosgrove: Obamacare now 'part of the fabric' of the U.S.

Cleveland Clinic CEO Toby Cosgrove said at the PRWeek Conference that the pharmaceutical industry has a responsibility to manage drug costs without the government stepping in

Five things for pharma marketers to know: Friday, October 14, 2016

Five things for pharma marketers to know: Friday, October 14, 2016

Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo

Five things for pharma marketers to know: Thursday, October 13, 2016

Five things for pharma marketers to know: Thursday, October 13, 2016

Aetna inks value-based deal with Merck in diabetes; new research claims co-pay cards increased drug spend; Xarelto data not affected by device

Sermo and Everyday Health partner in advertising-research deal

Sermo and Everyday Health partner in advertising-research deal

The partnership allows Sermo to expand the reach of its research initiatives and Everyday Health to scale its targeted advertising on the social platform.

Five things for pharma marketers to know: Wednesday, October 12, 2016

Five things for pharma marketers to know: Wednesday, October 12, 2016

Valeant is under fire for another price hike; Novartis and Queen Latifah raise awareness about heart failure; critics take aim at co-pay programs

Kite Pharma, developing a CAR-T therapy, hires new comms lead

Kite Pharma, developing a CAR-T therapy, hires new comms lead

The company hired Christine Cassiano, who is charged with preparing the communications strategy for the drugmaker's experimental cancer therapy.

Merck outspends Bristol-Myers Squibb on journal ads for Keytruda

Merck outspends Bristol-Myers Squibb on journal ads for Keytruda

Merck doled out more than $2 million to target doctors in the first half of the year, while BMS spent only $863,000.

OPINION

Email Newsletters